content: <PAGE>
  
                         SECURITIES AND EXCHANGE COMMISSION
  
                               Washington, D.C. 20549
  
                                      FORM 8-K
  
                                   CURRENT REPORT
                       Pursuant to Section 13 or 15(d) of the
                          Securities Exchange Act of 1934
  
           Date of Report (Date of earliest event reported): June 6, 2001
  
                               COR THERAPEUTICS, INC.
               (Exact name of registrant as specified in its charter)
  
         Delaware                0-19290                   94-3060271
  (State of jurisdiction) (Commission File No.) (IRS Employer Identification No.)
  
                               256 East Grand Avenue
                       South San Francisco, California 94080
               (Address of principal executive offices and zip code)
  
         Registrant's telephone number, including area code: (650) 244-6800
  
  
                                        1.
  <PAGE>
  
  Item 5.       Other Events
  
  On June 6, 2001, COR Therapeutics, Inc., a Delaware corporation, announced that
  it has entered into an agreement for the sale of $250 million of convertible
  senior notes ($300 million if the over-allotment option is exercised in full)
  through a Rule 144A offering to qualified institutional buyers.
  
  A copy of COR's press release announcing the private placement is attached
  hereto as Exhibit 99.1.
  
  Item 7.       Exhibits
  
  Exhibit 99.1  Press Release, dated June 6, 2001.
  
  
                                        2.
  <PAGE>
  
                                    SIGNATURES
  
  Pursuant to the requirements of the Securities Exchange Act of 1934, the
  Registrant has duly caused this report to be signed on its behalf by the
  undersigned hereunto duly authorized.
  
  
                              COR THERAPEUTICS, INC.
  
  Dated:  June 6, 2001        By:   /s/ Patrick Broderick
          ------------        ---------------------------------------
  
                                    Patrick Broderick
                                    Senior Vice President and General Counsel
  
  
                                        3.
metadata_documents: [{"type": "8-K", "sequence": "1", "filename": "d8k.txt", "description": "FORM 8-K", "secsgml_size_bytes": 2108}]
metadata_filer: {"company-data": {"conformed-name": "COR THERAPEUTICS INC / DE", "cik": "0000874865", "assigned-sic": "2834", "irs-number": "943060271", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-19290", "film-number": "1655460"}, "business-address": {"street1": "256 E GRAND AVE STE 80", "city": "SOUTH SAN FRANCISCO", "state": "CA", "zip": "94080", "phone": "4152446800"}}
text: SECURITIES AND EXCHANGE COMMISSION
  
                               Washington, D.C. 20549
  
                                      FORM 8-K
  
                                   CURRENT REPORT
                       Pursuant to Section 13 or 15(d) of the
                          Securities Exchange Act of 1934
  
           Date of Report (Date of earliest event reported): June 6, 2001
  
                               COR THERAPEUTICS, INC.
               (Exact name of registrant as specified in its charter)
  
         Delaware                0-19290                   94-3060271
  (State of jurisdiction) (Commission File No.) (IRS Employer Identification No.)
  
                               256 East Grand Avenue
                       South San Francisco, California 94080
               (Address of principal executive offices and zip code)
  
         Registrant's telephone number, including area code: (650) 244-6800
  
                                        1.
  Item 5.       Other Events
  
  On June 6, 2001, COR Therapeutics, Inc., a Delaware corporation, announced that
  it has entered into an agreement for the sale of $250 million of convertible
  senior notes ($300 million if the over-allotment option is exercised in full)
  through a Rule 144A offering to qualified institutional buyers.
  
  A copy of COR's press release announcing the private placement is attached
  hereto as Exhibit 99.1.
  
  Item 7.       Exhibits
  
  Exhibit 99.1  Press Release, dated June 6, 2001.
  
                                        2.
  SIGNATURES
  
  Pursuant to the requirements of the Securities Exchange Act of 1934, the
  Registrant has duly caused this report to be signed on its behalf by the
  undersigned hereunto duly authorized.
  
                              COR THERAPEUTICS, INC.
  
  Dated:  June 6, 2001        By:   /s/ Patrick Broderick
          ------------        ---------------------------------------
  
                                    Patrick Broderick
                                    Senior Vice President and General Counsel
  
                                        3.